Pharma
Stocks Outlook for the week – 09 to 13.05.2016
Mixed next week; earnings to be in
focus
( www.rupeedesk.in )
Pharmaceutical stocks are seen mixed
next week, with Jan-Mar earnings of Cadila Healthcare, Dr
Reddy's Laboratories and Glenmark
Pharmaceuticals key triggers for their scrips. Cadila Healthcare is
seen reporting a consolidated net
profit of 3.79 bln rupees, up 8.3% on year. Dr Reddy's Laboratories is expected
to report a 6.6% growth in its Jan-Mar consolidated net profit to 5.5 bln
rupees. Increased competition in Valcyte generic and a likely write-off in its
Venezuela earnings could weigh on result.
Wockhardt is likely to be in focus on
Monday, after reporting 26% rise in its Jan-Mar consolidated net profit to 429
mln rupees. Pfizer may extend gains after reporting a 57% surge in its Jan-Mar
net
profit to 669.7 mln rupees on account
of lower tax outgo and rise in other income. Yesterday, the
stock ended up 2%. Market
participants remain upbeat on Cipla and Aurobindo Pharma as the
companies are seen reporting strong
earnings. Aurobindo Pharma is on top of the radar of many
analysts, due to the company's strong
drug pipeline. Considers the stock as its top pick as it filed the
maximum number of drug master files
in 2015-16 (Apr-Mar) at 12.